MCM
RNAC icon

MAI Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

MAI Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148 Buy
+24
New +$171 ﹤0.01% 4686

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAI Capital Management's RNAC Position: Q1 2026 in Review

MAI Capital Management opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 24 shares worth $148. The stake represents ﹤0.01% of the portfolio and ranks #4686 among its holdings.

83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • MAI Capital Management held 24 shares of Cartesian Therapeutics worth $148 as of Q1 2026.
  • Cartesian Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Cartesian Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4686 holding.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.